CN103142491A - 一种单磷酸阿糖腺苷微球给药系统及其制备方法 - Google Patents
一种单磷酸阿糖腺苷微球给药系统及其制备方法 Download PDFInfo
- Publication number
- CN103142491A CN103142491A CN2013100483036A CN201310048303A CN103142491A CN 103142491 A CN103142491 A CN 103142491A CN 2013100483036 A CN2013100483036 A CN 2013100483036A CN 201310048303 A CN201310048303 A CN 201310048303A CN 103142491 A CN103142491 A CN 103142491A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- vidarabine phosphate
- preparation
- vidarabine
- chitosan microball
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- UDMBCSSLTHHNCD-UHTZMRCNSA-N [(2r,3s,4s,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O UDMBCSSLTHHNCD-UHTZMRCNSA-N 0.000 title claims description 37
- 238000012377 drug delivery Methods 0.000 title abstract description 11
- 229920001661 Chitosan Polymers 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 238000004132 cross linking Methods 0.000 claims abstract description 12
- 238000003756 stirring Methods 0.000 claims abstract description 11
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 8
- 239000002270 dispersing agent Substances 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 6
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 5
- 239000004094 surface-active agent Substances 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 24
- 239000011806 microball Substances 0.000 claims description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000003208 petroleum Substances 0.000 claims description 10
- 230000006196 deacetylation Effects 0.000 claims description 7
- 238000003381 deacetylation reaction Methods 0.000 claims description 7
- 229940057995 liquid paraffin Drugs 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- NWGKJDSIEKMTRX-MDZDMXLPSA-N Sorbitan oleate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)C1OCC(O)C1O NWGKJDSIEKMTRX-MDZDMXLPSA-N 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003361 porogen Substances 0.000 claims description 3
- IVKNZCBNXPYYKL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 IVKNZCBNXPYYKL-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 150000003904 phospholipids Chemical group 0.000 claims description 2
- 238000005086 pumping Methods 0.000 claims description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 2
- 239000008118 PEG 6000 Substances 0.000 claims 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 claims 1
- 230000000850 deacetylating effect Effects 0.000 claims 1
- BHTJEPVNHUUIPV-UHFFFAOYSA-N pentanedial;hydrate Chemical group O.O=CCCCC=O BHTJEPVNHUUIPV-UHFFFAOYSA-N 0.000 claims 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 abstract description 8
- 229960003636 vidarabine Drugs 0.000 abstract description 8
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 238000013268 sustained release Methods 0.000 abstract description 3
- 239000012730 sustained-release form Substances 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 abstract description 2
- 239000008346 aqueous phase Substances 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000012071 phase Substances 0.000 abstract 1
- 238000007711 solidification Methods 0.000 abstract 1
- 230000008023 solidification Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000000243 solution Substances 0.000 description 6
- 238000013019 agitation Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 229940048102 triphosphoric acid Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012690 ionic polymerization Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310048303.6A CN103142491B (zh) | 2013-02-06 | 2013-02-06 | 一种单磷酸阿糖腺苷微球给药系统及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310048303.6A CN103142491B (zh) | 2013-02-06 | 2013-02-06 | 一种单磷酸阿糖腺苷微球给药系统及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103142491A true CN103142491A (zh) | 2013-06-12 |
CN103142491B CN103142491B (zh) | 2015-07-15 |
Family
ID=48541008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310048303.6A Active CN103142491B (zh) | 2013-02-06 | 2013-02-06 | 一种单磷酸阿糖腺苷微球给药系统及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103142491B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105232571A (zh) * | 2015-09-28 | 2016-01-13 | 海南中化联合制药工业股份有限公司 | 一种单磷酸阿糖腺苷药物组合物 |
CN112250511A (zh) * | 2020-10-20 | 2021-01-22 | 南开大学 | 一种新型复合型缓释氧化微球及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001072281A2 (en) * | 2000-03-24 | 2001-10-04 | Biosphere Medical Inc. | Microspheres for active embolization |
US20050042173A1 (en) * | 2001-11-21 | 2005-02-24 | Jerome Besse | Micronized film-forming powder comprising an active substance |
CN1923173A (zh) * | 2006-02-24 | 2007-03-07 | 济南康泉医药科技有限公司 | 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂 |
WO2008001341A1 (en) * | 2006-06-27 | 2008-01-03 | Biovail Laboratories International Srl | Multiparticulate osmotic delivery system |
CN101716161A (zh) * | 2009-11-26 | 2010-06-02 | 辽宁大学 | 一种新的胸腺肽壳聚糖微球口服药物制剂及其制备方法 |
CN102525947A (zh) * | 2012-01-06 | 2012-07-04 | 石河子大学医学院第一附属医院 | 阿苯达唑壳聚糖微球组合物及其制备方法 |
CN102895255A (zh) * | 2012-10-31 | 2013-01-30 | 海南锦瑞制药股份有限公司 | 一种单磷酸阿糖腺苷的药用组合物及其制备方法 |
-
2013
- 2013-02-06 CN CN201310048303.6A patent/CN103142491B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001072281A2 (en) * | 2000-03-24 | 2001-10-04 | Biosphere Medical Inc. | Microspheres for active embolization |
US20050042173A1 (en) * | 2001-11-21 | 2005-02-24 | Jerome Besse | Micronized film-forming powder comprising an active substance |
CN1923173A (zh) * | 2006-02-24 | 2007-03-07 | 济南康泉医药科技有限公司 | 一种同载抗癌抗生素及其增效剂的抗癌药物缓释剂 |
WO2008001341A1 (en) * | 2006-06-27 | 2008-01-03 | Biovail Laboratories International Srl | Multiparticulate osmotic delivery system |
CN101716161A (zh) * | 2009-11-26 | 2010-06-02 | 辽宁大学 | 一种新的胸腺肽壳聚糖微球口服药物制剂及其制备方法 |
CN102525947A (zh) * | 2012-01-06 | 2012-07-04 | 石河子大学医学院第一附属医院 | 阿苯达唑壳聚糖微球组合物及其制备方法 |
CN102895255A (zh) * | 2012-10-31 | 2013-01-30 | 海南锦瑞制药股份有限公司 | 一种单磷酸阿糖腺苷的药用组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
杨铁耀等: "阿糖腺昔班微囊的研究", 《中国医药工业杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105232571A (zh) * | 2015-09-28 | 2016-01-13 | 海南中化联合制药工业股份有限公司 | 一种单磷酸阿糖腺苷药物组合物 |
CN112250511A (zh) * | 2020-10-20 | 2021-01-22 | 南开大学 | 一种新型复合型缓释氧化微球及其制备方法 |
CN112250511B (zh) * | 2020-10-20 | 2021-10-15 | 南开大学 | 一种新型复合型缓释氧化微球及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103142491B (zh) | 2015-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102988274B (zh) | 用于治疗肿瘤的药物缓释血管栓塞凝胶剂及其制备方法 | |
CN102302457B (zh) | 伊维菌素缓释微球的制备方法 | |
CN101249077A (zh) | 一种可降解聚合物多孔微球的制备方法及其用途 | |
CN107233302A (zh) | 一种纳米纤维素/聚多巴胺复合智能凝胶药物缓释材料的制备方法 | |
CN101612128B (zh) | 海藻酸无机纳米复合凝胶微球及其制备方法 | |
CN104382918A (zh) | 一种用于肿瘤局部注射的阿霉素脂质体温敏凝胶 | |
CN104306325A (zh) | 一种抗肿瘤水凝胶的制备方法 | |
CN104644547B (zh) | 一种长效头孢噻肟钠注射剂及其制备方法 | |
CN105131182A (zh) | 普朗尼克-聚(β-氨基酯)聚合物及其合成和应用方法 | |
CN103142491B (zh) | 一种单磷酸阿糖腺苷微球给药系统及其制备方法 | |
CN105663033B (zh) | 瘤内注射用原位温敏聚合物凝胶纳米组合物及应用 | |
CN107715169A (zh) | 含plga纳米微粒的海藻酸钠载药复合栓塞微球的制备方法及产品 | |
CN103228296B (zh) | 苯达莫司汀阴离子-阳离子型环聚糖组合物 | |
CN101836970A (zh) | 一种聚丙烯酸纳米凝胶微球及其制法和用途 | |
CN101317832B (zh) | 白藜芦醇口服纳米给药系统 | |
CN102357071B (zh) | 载紫杉醇纳米微泡及其制备方法 | |
KR20110114914A (ko) | 약물 전달을 위한 pH-민감성 나노입자 및 이의 제조방법 | |
Ahmad et al. | Chitosan-based bionanocomposites in drug delivery | |
CN104224688A (zh) | 负载纳米药物的丙烯酸酯化透明质酸水凝胶及其制备方法 | |
CN103356480B (zh) | 一种齐墩果酸纳米混悬剂及其制备方法 | |
CN1748671A (zh) | 含抗有丝分裂药物的缓释注射剂 | |
Liu et al. | Metal-organic framework-based injectable in situ gel for multi-responsive insulin delivery | |
CN102188391B (zh) | 制备粒细胞-巨噬细胞集落刺激因子微球的方法 | |
CN101884623B (zh) | 一种左旋多巴甲酯缓释微球组合物及其制备方法 | |
CN104208711B (zh) | 壳聚糖半流体缓释凝胶及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 510620 Guangdong Province, Guangzhou City Sports Road No. 103 A Victoria Plaza, 49 floor 4901 Applicant after: Xianqiang Pharmaceutical Co., Ltd., Guangdong Address before: 510620 Guangdong Province, Guangzhou City Sports Road No. 103 A Victoria Plaza, 49 floor 4901 Applicant before: Guangdong Xianqiang Pharmaceutical Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: GUANGDONG XIANQIANG PHARMACEUTICAL CO., LTD. TO: XIANQIANG PHARMACEUTICAL CO., LTD., GUANGDONG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201118 Address after: No.6, Gongye Avenue, Conghua Economic Development Zone, Guangzhou City, Guangdong Province Patentee after: GUANGDONG XIANQIANG PHARMACEUTICAL Co.,Ltd. Patentee after: Guangdong Zhongsheng Pharmaceutical Co.,Ltd. Address before: 510620 Guangdong Province, Guangzhou City Sports Road No. 103 A Victoria Plaza, 49 floor 4901 Patentee before: GUANGDONG XIANQIANG PHARMACEUTICAL Co.,Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Huang Caifeng Document name: Notice of conformity |
|
DD01 | Delivery of document by public notice |